Cargando…

Quantification of Lipoteichoic Acid in Hemodialysis Patients With Central Venous Catheters

Hemodialysis patients with central venous catheters (CVCs) have chronic systemic inflammation, the source of which may be related to intraluminal bacterial biofilm. There is currently no non-invasive method to adequately evaluate intraluminal biofilm. Lipoteichoic acid (LTA) is a Gram-positive bacte...

Descripción completa

Detalles Bibliográficos
Autores principales: Barton Pai, Amy, Garba, Adinoyi, Neumann, Paul, Prokopienko, Alexander J., Costello, Gabrielle, Dean, Michael C., Narsipur, Sriram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6230575/
https://www.ncbi.nlm.nih.gov/pubmed/30456212
http://dx.doi.org/10.3389/fmed.2018.00308
_version_ 1783370100940734464
author Barton Pai, Amy
Garba, Adinoyi
Neumann, Paul
Prokopienko, Alexander J.
Costello, Gabrielle
Dean, Michael C.
Narsipur, Sriram
author_facet Barton Pai, Amy
Garba, Adinoyi
Neumann, Paul
Prokopienko, Alexander J.
Costello, Gabrielle
Dean, Michael C.
Narsipur, Sriram
author_sort Barton Pai, Amy
collection PubMed
description Hemodialysis patients with central venous catheters (CVCs) have chronic systemic inflammation, the source of which may be related to intraluminal bacterial biofilm. There is currently no non-invasive method to adequately evaluate intraluminal biofilm. Lipoteichoic acid (LTA) is a Gram-positive bacterial cell wall component that is spontaneously shed. The purpose of this study was to determine whether LTA could be quantified in biological samples and to evaluate potential relationships to markers of inflammation. Heparin-locked catheter aspirate was drawn from both the arterial and venous ports of each CVC prior to dialysis initiation. Venous blood from the dialysis circuit was collected 30 min after dialysis initiation. LTA was quantified in aspirate and plasma. Key markers of inflammation (interleukin-6, and hepcidin) and endothelial dysfunction (soluble vascular endothelial cadherin) were also determined in plasma samples. Catheter aspirate and systemic blood samples were obtained from 40 hemodialysis patients. The median (range) duration of catheter use was 130 (20–1635) days. Unexpectedly, median (range) plasma LTA concentrations (ng/mL) were significantly higher than catheter aspirate LTA concentrations [3.93 (0.25–15) vs. 2.38 (0.1–8.1), respectively, p = 0.01] in the majority (70%) of patients. Area under the receiver operator characteristic (ROC) curve showed good potential prognostic value of catheter aspirate LTA predicting systemic LTA concentrations with an area under the curve of 0.815 (95% CI, 0.68–0.95). A significant correlation was found between LTA and serum ferritin (r = 0.32, p = 0.04), however, there were no significant correlations between LTA and the other inflammation biomarkers assessed. LTA is quantifiable in aspirate and plasma of hemodialysis patients with CVCs and warrants further investigation to determine potential clinical application to intraluminal biofilm evaluation.
format Online
Article
Text
id pubmed-6230575
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-62305752018-11-19 Quantification of Lipoteichoic Acid in Hemodialysis Patients With Central Venous Catheters Barton Pai, Amy Garba, Adinoyi Neumann, Paul Prokopienko, Alexander J. Costello, Gabrielle Dean, Michael C. Narsipur, Sriram Front Med (Lausanne) Medicine Hemodialysis patients with central venous catheters (CVCs) have chronic systemic inflammation, the source of which may be related to intraluminal bacterial biofilm. There is currently no non-invasive method to adequately evaluate intraluminal biofilm. Lipoteichoic acid (LTA) is a Gram-positive bacterial cell wall component that is spontaneously shed. The purpose of this study was to determine whether LTA could be quantified in biological samples and to evaluate potential relationships to markers of inflammation. Heparin-locked catheter aspirate was drawn from both the arterial and venous ports of each CVC prior to dialysis initiation. Venous blood from the dialysis circuit was collected 30 min after dialysis initiation. LTA was quantified in aspirate and plasma. Key markers of inflammation (interleukin-6, and hepcidin) and endothelial dysfunction (soluble vascular endothelial cadherin) were also determined in plasma samples. Catheter aspirate and systemic blood samples were obtained from 40 hemodialysis patients. The median (range) duration of catheter use was 130 (20–1635) days. Unexpectedly, median (range) plasma LTA concentrations (ng/mL) were significantly higher than catheter aspirate LTA concentrations [3.93 (0.25–15) vs. 2.38 (0.1–8.1), respectively, p = 0.01] in the majority (70%) of patients. Area under the receiver operator characteristic (ROC) curve showed good potential prognostic value of catheter aspirate LTA predicting systemic LTA concentrations with an area under the curve of 0.815 (95% CI, 0.68–0.95). A significant correlation was found between LTA and serum ferritin (r = 0.32, p = 0.04), however, there were no significant correlations between LTA and the other inflammation biomarkers assessed. LTA is quantifiable in aspirate and plasma of hemodialysis patients with CVCs and warrants further investigation to determine potential clinical application to intraluminal biofilm evaluation. Frontiers Media S.A. 2018-11-05 /pmc/articles/PMC6230575/ /pubmed/30456212 http://dx.doi.org/10.3389/fmed.2018.00308 Text en Copyright © 2018 Barton Pai, Garba, Neumann, Prokopienko, Costello, Dean and Narsipur. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Barton Pai, Amy
Garba, Adinoyi
Neumann, Paul
Prokopienko, Alexander J.
Costello, Gabrielle
Dean, Michael C.
Narsipur, Sriram
Quantification of Lipoteichoic Acid in Hemodialysis Patients With Central Venous Catheters
title Quantification of Lipoteichoic Acid in Hemodialysis Patients With Central Venous Catheters
title_full Quantification of Lipoteichoic Acid in Hemodialysis Patients With Central Venous Catheters
title_fullStr Quantification of Lipoteichoic Acid in Hemodialysis Patients With Central Venous Catheters
title_full_unstemmed Quantification of Lipoteichoic Acid in Hemodialysis Patients With Central Venous Catheters
title_short Quantification of Lipoteichoic Acid in Hemodialysis Patients With Central Venous Catheters
title_sort quantification of lipoteichoic acid in hemodialysis patients with central venous catheters
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6230575/
https://www.ncbi.nlm.nih.gov/pubmed/30456212
http://dx.doi.org/10.3389/fmed.2018.00308
work_keys_str_mv AT bartonpaiamy quantificationoflipoteichoicacidinhemodialysispatientswithcentralvenouscatheters
AT garbaadinoyi quantificationoflipoteichoicacidinhemodialysispatientswithcentralvenouscatheters
AT neumannpaul quantificationoflipoteichoicacidinhemodialysispatientswithcentralvenouscatheters
AT prokopienkoalexanderj quantificationoflipoteichoicacidinhemodialysispatientswithcentralvenouscatheters
AT costellogabrielle quantificationoflipoteichoicacidinhemodialysispatientswithcentralvenouscatheters
AT deanmichaelc quantificationoflipoteichoicacidinhemodialysispatientswithcentralvenouscatheters
AT narsipursriram quantificationoflipoteichoicacidinhemodialysispatientswithcentralvenouscatheters